- Home
- MITQ vs GLMD Comparison
MITQ vs GLMD Comparison
Compare MITQ & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MITQ | GLMD |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.6M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MITQ | GLMD |
|---|---|---|
| Price | $0.72 | $1.21 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 72.1K | ★ 6.3M |
| Earning Date | 11-14-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,477,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.74 |
| 52 Week High | $1.66 | $3.61 |
Technical Indicators
Market Signals| Indicator | MITQ | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 58.23 |
| Support Level | $0.70 | $0.81 |
| Resistance Level | $0.80 | $0.99 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 63.29 | 97.90 |
Price Performance
Historical ComparisonAbout MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.